Ansuvimab-zykl
Ansuvimab-zykl
Ansuvimab-zykl (pronounced as an-soo-vi-mab zykl) is a monoclonal antibody medication used for the treatment of Ebola virus disease.
Etymology
The name "Ansuvimab-zykl" is derived from the International Nonproprietary Names (INN), where "Ansu-" refers to antibody, "-vi-" refers to viral, "-mab" is indicative of monoclonal antibody, and "-zykl" is a suffix used in the INN system for Ebola virus-related treatments.
Usage
Ansuvimab-zykl is used in the treatment of Ebola virus disease, a severe and often fatal illness in humans caused by the Ebola virus. The medication works by binding to the virus, thereby neutralizing it and preventing it from infecting new cells.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Ebola virus disease: A severe, often fatal illness in humans caused by the Ebola virus.
- Ebola virus: A virus that causes severe bleeding, organ failure, and can lead to death.
- International Nonproprietary Names: The official non-proprietary or generic names given to a pharmaceutical substance, as designated by the World Health Organization.
External links
- Medical encyclopedia article on Ansuvimab-zykl
- Wikipedia's article - Ansuvimab-zykl
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski